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Abstract
Background and purpose:  Recent findings suggest that a gait assessment at a discrete moment in a clinic or labo‑
ratory setting may not reflect functional, everyday mobility. As a step towards better understanding gait during daily
life in neurological populations, we compared gait measures that best discriminated people with multiple sclerosis
(MS) and people with Parkinson’s Disease (PD) from their respective, age-matched, healthy control subjects (MS-Ctl,
PD-Ctl) in laboratory tests versus a week of daily life monitoring.
Methods:  We recruited 15 people with MS (age mean ± SD: 49 ± 10 years), 16 MS-Ctl (45 ± 11 years), 16 people with
idiopathic PD (71 ± 5 years), and 15 PD-Ctl (69 ± 7 years). Subjects wore 3 inertial sensors (one each foot and lower
back) in the laboratory followed by 7 days during daily life. Mann–Whitney U test and area under the curve (AUC)
compared differences between PD and PD-Ctl, and between MS and MS-Ctl in the laboratory and in daily life.
Results:  Participants wore sensors for 60–68 h in daily life. Measures that best discriminated gait characteristics in
people with MS and PD from their respective control groups were different between the laboratory gait test and
a week of daily life. Specifically, the toe-off angle best discriminated MS versus MS-Ctl in the laboratory (AUC [95%
CI] = 0.80 [0.63–0.96]) whereas gait speed in daily life (AUC = 0.84 [0.69–1.00]). In contrast, the lumbar coronal range
of motion best discriminated PD versus PD-Ctl in the laboratory (AUC = 0.78 [0.59–0.96]) whereas foot-strike angle in
daily life (AUC = 0.84 [0.70–0.98]). AUCs were larger in daily life compared to the laboratory.
Conclusions: Larger AUC for daily life gait measures compared to the laboratory gait measures suggest that daily
life monitoring may be more sensitive to impairments from neurological disease, but each neurological disease may
require different gait outcome measures.
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Background
Gait impairments are very common in patients with neurological disorders, leading to an elevated risk of falls and
reduced quality of life [1–3]. Quantitative gait assessment
can often determine the problem(s) underlying the gait
impairment and then can be useful to test an efficacy of
a new intervention. However, until recently, quantitative
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gait assessments were limited to specialized laboratories,
under well-controlled conditions. Although laboratory
gait assessments provide information about gait under
controlled conditions, they may not reflect actual, functional gait performance during daily activities [4–6]. It
is likely that increased attention to the walking task and
awareness of being observed (Hawthorne effect) minimizes gait impairments in the laboratory while divided
attention, cluttered environments, varied sensory conditions, and fatigue may result in worse gait impairments
during daily life. Thus, gait assessment in the laboratory reflects a person’s capacity (what a person can do),
whereas gait during daily life reflects a person’s functional
performance (what a person is actually doing) [5, 6]. This
understanding is important while conducting research
as we might see only optimal performance during clinical or laboratory visits and daily performance may be
worse than what is observed in these prescribed tasks.
As a result, clinicians might underestimate potential gait
impairments related to daily life functional abilities.
Further, specific types of mobility impairments differ
depending upon the neurological disorder. For example, gait in people with MS is characterized by reduced
endurance, spasticity, and ataxia, whereas gait in people
with PD is characterized by bradykinesia, shuffling, rigidity, freezing, and difficulties turning [7–10]. Slowed gait
speed is very common with any neurological disorder or
age [11]. However, slow gait is a general, universal characteristic of impaired mobility and hence, may not be the
most specific nor discriminative mobility impairment in
each neurological disorder.
Recently, the use of wearable technology has made it
feasible to quantify gait in the laboratory and during daily
life [12–30]. Several studies have compared the quality of
mobility in the laboratory with daily life walking bouts [5,
14, 31–33]; however, these studies did not compare similar gait bout lengths in the two environments (laboratory
versus daily life) except for the one recent study in children with cerebral palsy [32]. Specifically, Del Din et al.
[14] compared 10-m walking bout in the laboratory to all
walking bouts during daily life in people with PD, Storm
et al. [31] compared 15-m and 1-min walking bout in the
laboratory to all bouts with < 50 steps, between 51 to 100
steps and > 100 steps in people with MS. Hillel et al. [5]
compared 1-min laboratory walking bout to daily life
walking bout of 30-s only in people with PD. Shema-Shiratzky et al. [33] compared the first 30-s of 1-min laboratory walking bout to daily life walking bout of 30-s and
more in people with MS. Matching gait bout length is
important because many gait measures change with the
duration of a walking bout [14], [34]. In addition, people
very seldom, if ever, walk for more than 1-min continuously or in a straight line for over 10-m during daily life
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like they do in laboratory tests [4, 5, 14, 31]. Thus, comparisons of strides taken from long, steady-state gait in
the laboratory with all the strides measured in daily life
are confounded by differences in gait bout length. Hence,
in this study, we focused on short walk test in the laboratory and compared the gait characteristics in the laboratory to similar short walking bouts during daily life.
In this study, we aimed to identify a set of gait measures
that best discriminated gait characteristics from a single
short walk gait test in the laboratory between people with
MS and their age-matched healthy control subjects (MSCtl), and between people with PD and their older, agematched healthy control subjects (PD-Ctl) and compared
those gait quality measures to a week of daily life gait
quality measures from a similar short bout length using
wearable sensors. We investigated whether gait measures that best discriminate gait impairments in MS and
PD versus their respective control cohorts during laboratory assessments remain the same during a week of daily
life assessment. Further, we investigated the group differences between laboratory and daily life gait measures
for MS, MS-Ctl, PD, and PD-Ctl. We hypothesized that:
(1) different gait measures would best discriminate PD
vs. PD-Ctl and MS vs. MS-Ctl in the laboratory and daily
life, and (2) daily life gait would be more discriminative
than laboratory measures for both neurological groups.
Recent studies have shown that the laboratory gait measures do not reliably reflect daily life gait measures in
people with PD and MS [5, 14, 33]. Hence, we expected
different gait measures would discriminate in the laboratory and daily life for both neurological groups. We also
expected that daily life would provide a more complete
picture of functional performance in a complex environment, such that group differences would be more evident
in daily life compared to laboratory gait measures. Further, we explored which specific gait measures were the
most discriminative for the PD and the MS groups, both
in the laboratory and daily life.

Methods
Participants

We recruited people with MS, age-matched MS-Ctl,
people with PD, and age-matched PD-Ctl for this study
which is the part of a larger, longer study to identify gait
measures that predict prospective falls in MS and PD.
Our cohort with MS was younger than the cohort with
PD, so we recruited younger and older control groups
for comparison. Inclusion and exclusion criteria were the
same as described in Shah et al. [35]. Specifically, inclusion criteria for PD were a diagnosis of idiopathic Parkinson’s disease from movement disorders neurologist
with the United Kingdom Parkinson’s disease Society
Brain Bank criteria, Hoehn & Yahr scores of II-IV, and
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complaints about gait. Inclusion criteria for MS were
a diagnosis of relapsing–remitting MS confirmed by a
neurologist specialist, a mild-to-moderate MS-associated disability (patient-reported EDSS score ≤ 6.0), and
complaints about gait. Exclusion criteria for all subjects
included the inability to follow protocol instructions,
other factors affecting gait such as musculoskeletal disorders, uncorrected vision or vestibular problems, or
inability to stand or walk in the home without an assistive device. The experimental protocol was approved by
the Institutional Review Board of the Oregon Health &
Science University (eIRB #15578). The experimental
protocol was carried out in accordance with the institution’s ethical committee, and all the participants provided
informed written consent.
Laboratory data collection

In the laboratory, subjects were asked to wear 3 inertial
sensors (Opals by APDM Wearable Technologies, Portland, OR, USA; Fig. 1a); one sensor on top of each foot,
and one over the lower lumbar on an elastic belt. Each
Opal sensor includes a tri-axial accelerometer, gyroscope,
and magnetometer with a sampling rate of 128 Hz. The
Opal is lightweight (22 g), has a battery life of 16 h, and
includes 8 GB of storage, that can record over 30 days of
data. All the subjects performed the Instrumented Stand
and Walk test (ISAW) [36]. The ISAW consists of standing quietly for 30 s, followed by a verbal instruction to
initiate gait, walk 7 m, turn 180 degrees after crossing
a line on the ground, and return to the initial starting

Fig. 1 Sensor placement on feet. a Opal inertial sensor on foot for
laboratory testing. b Instrumented sock prototype for daily life data
collection. Note inertial sensor located over lateral metatarsals and
battery located just above lateral malleolus
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position [36]. The ISAW test was designed to measure
postural sway, step initiation, gait, and turning, all in one
short test. Individuals with MS completed estimates of
the severity of MS with Patient-Reported Expanded Disability Status Scale (PREDSS) [37, 38], walking ability
with Multiple Sclerosis Walking Scale (MSWS-12) [39],
and fatigue with Modified Fatigue Index Scale (MFIS)
[40]). PD severity was assessed by a certified researcher
using the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part III [41]).
All subjects were tested in the laboratory 1 h after taking
their regular medication intake (ON-medication state),
because most of the time, subjects attempt to be in the
ON-medication state in daily life.
Daily life gait data collection

Subjects were asked to wear instrumented socks (prototype developed by APDM Wearable Technologies,
Portland, OR, USA; Fig. 1b) on each foot, and one Opal
sensor over the lower lumbar area with an elastic belt.
They wore the sensors for at least 8 h/day for a week of
daily life. To reduce the burden on participants of trying to securely attach the Opal monitors to the outside
of their shoes, APDM Wearable Technologies designed
an instrumented sock that wraps around the participant’s foot and ankle with the inertial sensor inserted into
a small, lightweight pocket in the foot area. The inertial
sensor within the sock is located on the dorsum of the
foot like the Opal sensors worn in the laboratory, The
main unit containing the battery is located in a second
pocket just above the lateral malleolus. To maximize fit,
the socks come in different sizes, and the Velcro attachment around the foot and ankle is adjustable to ensure
that a snug fit and that the sensor does not move on the
foot while being worn. Thus the inertial system fits into
the instrumented sock for ease of application and safe,
unobtrusive use. The instrumented socks and Opals have
the same inertial sensors with the same sensor specifications but different form factor. The instrumented socks
are synchronized with the Opal worn on the lumbar area.
This allowed subjects to comfortably wear the instrumented socks in their shoes or slippers, and without a
visually-distracting external strap attachment. It also
eliminated the task of securing the monitors on the shoes,
especially important for people (such as people with PD),
who have difficulty with fine motor movements, such as
tying shoelaces. The subjects removed the socks and the
belt at night to recharge the batteries. Data were stored in
the 8 GB internal memory of the Opals and socks. Subjects returned instrumented socks either by mail using a
pre-paid box after completion of a week of data collection or to a research assistant who met subjects at their
homes. Data were uploaded to a secure cloud-based

Shah et al. J NeuroEngineering Rehabil

(2020) 17:159

database upon return of the devices and downloaded to a
local computer for further processing using the same gait
algorithms for laboratory and daily life gait (after identification of appropriate length gait bouts).
Measures of gait

The algorithms used for extracting spatial and temporal
measures of gait and turning are identical for laboratory
and daily life gait and have been detailed previously [35,
42]. In addition, the daily life algorithm first searches for
possible bouts of walking using a time-domain approach
to inertial sensor data from the feet and for turns based
on yaw rotational orientation of the pelvis. Second, individual steps are combined into potential bouts of walking, as long as the duration from one step to the next step
is no longer than 2.5 s. Finally, each possible bout that
contains at least 3 steps and is at least 3 s in duration is
processed with the commercial gait analysis algorithms
included in Mobility Laboratory (APDM Wearable Technologies, Portland, Oregon) [36, 43, 44]. Our gait analysis algorithm uses the Unscented Kalman Filter to fuse
information from the accelerometers, gyroscopes, and
magnetometers to precisely estimate the orientation and
position trajectory of each foot between quiet stance
periods [45, 46]. This approach reduces the problem of
tracking over a long period of time.
To compare between in-laboratory and daily life gait
measures, we used only gait bouts that had a similar
number of strides during the ISAW test in the laboratory and during free-living daily activities (4–15 strides
in about). Specifically, we calculated number valid of
strides for the ISAW test in the laboratory for all participants and found that it ranged between 4 to 15 strides, so
for the bout analysis in daily life we used the same range
(4–15 strides) corresponding to the stride range observed
in the laboratory ISAW test. In total, we chose 13 gait
measures (see Fig. 3 and Additional file 1: Table S1) that
are commonly used to characterize gait in the laboratory
and grouped them into three aspects of gait for simplicity: 3 upper-body, 5 spatial, and 5 temporal measures of
gait [47]. We avoided comparing the coefficient of variation measures as it is affected by the environment and
by bout length [48], and also the number of strides in a
bout for our analysis was less than the minimum number
of strides required to accurately calculate a coefficient of
variation (20 strides) [49, 50].
Statistical analysis

The normality of data was determined with Shapiro–
Wilk tests and parametric analysis was used, unless otherwise stated. Independent t-tests or Mann–Whitney U
tests (if not normally distributed) were used to compare
between-group differences in subject characteristics,
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adherence, and total weekly walking bouts. As not all gait
quality measures in the laboratory and during daily life
were normally distributed, to be consistent, non-parametric test (Mann–Whitney U test) was used to compare
differences between groups for all gait measures (i.e., MS
vs MS-Ctl and PD vs PD-Ctl). In addition, we computed
Receiving Operating Characteristics (ROC) and calculated the Area Under Curve (AUC) [51] to discriminate
gait measures in people with MS from MS-Ctl and people with PD from PD-Ctl, and ordered measures from the
highest to lowest AUC value. Paired Wilcoxon tests were
used to compare the laboratory and daily life gait measures for MS, MS-Ctl, PD, and PD-Ctl. All statistical analysis was performed using R Version 1.1.456 software. The
statistical significance was set to p < 0.05, and we used
threshold of p ≤ 0.004 based on the Bonferroni’s correction (due to 13 multiple comparisons) just to prioritize
gait measures.

Results
Group characteristics and adherence

Fifteen people with MS, 16 age-match MS-Ctl, 16 people with PD (Hoehn and Yahr stage with II (n = 26), III
(n = 2), and IV (n = 1)), and 15 age-matched PD-Ctl participated in the study. Table 1 shows the demographics
and activity characteristics of subjects who participated
in this study. Age, height, and weight were similar
between the MS and MS-Ctl and between the PD and
PD-Ctl groups. Adherence to the weekly recordings
for each subject group was similar with 60.19 ± 11.02
(mean ± SD) hours in MS, 64.15 ± 9.59 h in MS-Ctl,
67.66 ± 12.53 h in PD, and 64.67 ± 10.13 h in PD-Ctl
of daily life data. The histogram in Fig. 2 illustrates the
number of strides in each bout during daily life, and it is
evident that the stride range (4–15 strides) in a bout considered for the analysis in this study captures the major
portion of participants’ daily activity.
Laboratory versus daily life gait measures discriminating
gait in MS from MS‑Ctl

Measures discriminating gait characteristics in people
with MS from MS-Ctl in laboratory versus daily life were
different (see Table 2 and Fig. 3a). Specifically, the toeoff angle was the most discriminative in the laboratory
(p = 0.004; AUC [95% CI] = 0.796 [0.628–0.964]) whereas
gait speed was in daily life (p = 0.001; AUC = 0.842
[0.686–0.998]). Stride length was the second best discriminative measure in the laboratory (p = 0.027;
AUC = 0.735 [0.556–0.915]) whereas the duration of
swing phase as percent of gait cycle was in daily life
(p = 0.002; AUC = 0.812 [0.648–0.977). Furthermore,
more gait measures discriminated MS from MS-Ctl in

Shah et al. J NeuroEngineering Rehabil

(2020) 17:159

Page 5 of 12

Table 1 Demographics, adherence, and weekly activity of each group
MS
(N = 15)
Mean
Age (yrs)

MS-Ctl
(N = 16)
SD

Mean

p
SD

PD
(N = 16)
Mean

SD

10.13

44.63

10.73

0.29

6.50

0.44

1.70

0.09

1.67

0.08

0.98

1.73

0.09

1.73

0.12

0.84

65.43

11.55

0.58

75.38

14.02

76.99

17.90

0.70

UPDRS III ON (#)

30.44

10.76

H & Y Stage (#)

2.25

0.56

72.36

21.03

4.27

0.70

MSWS (#)

29.00

8.91

MFIS (#)

38.80

17.01

68.6

SD

48.73

Weight (kg)

5.11

Mean

p

Height (m)
PREDSS (#)

70.5

PD-Ctl
(N = 15)

Total hours (#)

60.19

11.41

64.15

9.91

0.32

67.66

12.95

64.67

10.49

0.55

Total Bouts (#)

467.67

183.41

656.69

225.71

0.02

585.50

300.03

619.73

215.04

0.71

Bouts used for analysis (#)

228.33

113.40

282.88

118.96

0.20

292.25

145.99

272.33

95.73

0.91

MS multiple sclerosis, MS-Ctl age-matched control subjects corresponding to MS, PD Parkinson’s disease, PD-Ctl age-matched control subjects corresponding to PD,
PREDSS Patient-Reported Expanded Disability Status Scale, MSWS Multiple Sclerosis Walking Scale, MFIS Modified Fatigue Index Scale, UPDRS Unified Parkinson’s
Disease Rating Scale, H & Y Hoehn and Yahr

Fig. 2 Histogram of the grouped total of bout during daily life for each group. The dashed line indicates the range of the number of strides in the
bout used for the analysis
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Table 2 Comparison of gait measures between MS and control groups in the laboratory and during daily life
Gait measures

Laboratory

Daily Life

MS-Ctl
(N = 16)
Mean

Wilcox
p-value

MS
(N = 15)
SD

Mean

SD

MS-Ctl
(N = 16)
Mean

Wilcox
p-value

MS
(N = 15)
SD

Mean

SD

Cadence (steps/min)

114.11

9.69

112.59

10.9

0.770

106.92

8.36

99.57

7.68

0.005

Double Support (%)

20.3

2.65

22.06

4

0.129

22.67

3.55

26.85

3.61

0.002†

Elevation at Mid Swing (cm)

0.81

0.32

1.07

0.47

0.155

2.98

0.69

2.71

0.53

0.299

Gait Speed (m/s)

1.11

0.15

1

0.16

0.097

1

0.17

0.8

0.13

0.001†

Foot Strike Angle (degrees)

17.97

3.34

15.65

4.68

0.188

19.38

2.64

16.25

4.16

0.037

Toe Off Angle (degrees)

36.31

3.44

31.85

3.97

0.004†

27.97

3.83

23.96

4.01

0.017

1.06

0.09

1.08

0.11

0.767

1.17

0.1

1.25

0.1

0.017

Stride Duration (s)
Stride Length (m)

1.16

0.11

1.07

0.13

0.027

1.1

0.16

0.95

0.15

0.019

39.84

1.34

38.91

2.1

0.123

38.81

1.85

36.58

1.85

0.002†

Toe Out Angle (degrees)

9.57

4.45

11.13

6.16

0.358

17.93

8.47

18.89

11.51

0.599

Lumbar—Coronal ROM (degrees)

8.47

1.45

7.22

1.91

0.040

7.45

1.72

6.31

1.72

0.151

Swing (%)

Lumbar—Sagittal ROM (degrees)

6.18

2.26

6.15

1.86

0.752

6.87

1.15

6.87

1.15

0.740

Lumbar—Transverse ROM (deg)

8.75

2.85

9.79

2.57

0.286

16.62

2.87

16.62

1.72

0.338

Italics indicates p < 0.05, and † indicates if the p-value ≤ 0.004 level of significance after Bonferroni correction (that is, 0.05/13 = 0.004)

daily life (n = 3) compared to the laboratory (n = 1), after
the Bonferroni’s correction (13 multiple tests).
Laboratory versus daily life gait measures discriminating
gait in PD from PD‑Ctl

Most of the measures discriminating gait characteristics in people with PD from PD-Ctl in laboratory versus
daily life were different (see Table 3 and Fig. 3b). Specifically, the lumbar coronal range of motion was the most
discriminative in the laboratory (p = 0.010; AUC = 0.775
[0.589–0.961]) whereas the foot-strike angle was in daily
life (p = 0.001; AUC = 0.838 [0.697–0.978]). The footstrike angle was the second best discriminative in the laboratory (p = 0.011; AUC = 0.767 [0.578–0.955]) whereas
gait speed was in daily life (p = 0.003; AUC = 0.804
[0.632–0.976]). Furthermore, more daily life (n = 2) than
laboratory (n = 0) measures discriminated gait in the
PD group from the PD-Ctl group, after the Bonferroni’s
correction.
Laboratory versus daily life gait measures for each group

Generally, the gait characteristics in daily life compared
to the laboratory reflected a slowing down behavior in all
groups, and subjects performed better in the laboratory
compared to daily life (see Fig. 4). Specifically, looking at
the gait measures that were significant after the Bonferroni’s correction in PD and MS groups, gait speed (except
MS-Ctl), swing duration (% of the gait cycle), and the toeoff angle were significantly lower in daily life compared
to the laboratory in all groups. Further, double support
time was significantly longer in daily life compared to the

laboratory in all groups. In contrast, the foot strike angle
was not statistically significant between laboratory and
daily life in all groups except for MS-Ctl.

Discussion
In this study we used similar length, short walking bouts
in the laboratory and daily life to investigate whether the
best discriminative gait measures for PD and MS versus
their respective age-matched controls remain the same
in a laboratory walking test and daily life walking. Our
findings demonstrated that the best measures discriminating gait characteristics in a laboratory versus daily life
both in the MS and PD groups were different. Specifically, for people with MS, the toe-off angle was the most
discriminative in the laboratory, whereas gait speed best
discriminated in daily life. For people with PD, the lumbar coronal range of motion was the most discriminative
in the laboratory (although not significant after the Bonferroni’s correction), whereas foot- strike angle best discriminated in daily life.
Although the gait measures discriminating MS and
PD gait characteristics from their age-matched control
groups were different, we observed an increased in the
ability to discriminate neurological from control groups
(i.e., AUC) for daily life gait measures compared to laboratory gait measures. All groups showed improved
walking characteristics in the laboratory test compared
to daily life, even though we controlled for bout length,
unlike previous studies [5, 14]. For example, the gait
speed was significantly higher in laboratory compared
to daily life for all groups suggesting that the laboratory
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Fig. 3 AUC (in descending order with 95% CI) for each mobility measure discriminating a people with MS from MS-Ctl, and b people with PD from
PD-Ctl. The color-coding scheme is based on three aspects of gait
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Table 3 Comparison of gait measures between PD and control groups in the laboratory and during daily life
Gait measures

Laboratory

Daily Life

PD-Ctl
(N = 15)
Mean

Wilcox
p-value

PD
(N = 16)
SD

Mean

SD

PD-Ctl
(N = 15)
Mean

Wilcox
p-value

PD
(N = 16)
SD

Mean

SD
11.1

Cadence (steps/min)

114.49

9.65

116.94

7.67

0.446

101.37

8.07

104

Double Support (%)

21.88

2.88

20.41

3.76

0.151

27.18

5.67

27.39

5.04

0.922

0.446

Elevation at Mid Swing (cm)

0.95

0.61

1.05

0.6

0.693

3.29

0.99

3.29

0.9

0.800

Gait Speed (m/s)

1.07

0.15

1.05

0.15

0.828

0.89

0.13

0.73

0.15

0.003†

Foot Strike Angle (degrees)

16.94

5.27

12.81

4.56

0.011

17.67

3.52

11.57

5.09

0.001†

Toe Off Angle (degrees)

33.8

5.3

31.49

5.05

0.140

25.4

3.73

22.4

0.09

1.03

0.07

0.452

Stride Duration (s)
Stride Length (m)

1.06

1.23

0.11

1.21

4.67

0.027

0.13

0.495

1.12

0.13

1.08

0.16

0.553

1.04

0.12

0.85

0.18

0.006

38.99

1.39

39.67

1.95

0.151

37.04

1.87

36.81

2.23

0.830

Toe Out Angle (degrees)

8.66

7.5

9.31

8.51

1.000

19.63

9.53

17.02

8.8

0.495

Lumbar—Coronal ROM (degrees)

7.85

2.11

5.84

2.44

0.010

6.31

1.72

5.16

1.72

0.142

Swing (%)

Lumbar—Sagittal ROM (degrees)

5.81

2.44

5.58

2.55

0.711

6.31

1.15

6.88

1.72

0.854

Lumbar—Transverse ROM (degrees)

9.58

3.49

9.79

4.27

0.843

16.62

2.93

16.05

4.01

0.377

Italics indicates p < 0.05, and † indicates if the p-value ≤ 0.004 level of significance after Bonferroni correction (that is, 0.05/13 = 0.004)

walking while observed may be due to the Hawthorne
effect or to the lack of distractions and complexity of the
environment [5]. Interestingly, the difference between the
laboratory and daily life gait measures were the largest
(for example, gait speed, and percentage of double support during the gait cycle) for people with PD. The large
deterioration in gait characteristics during daily life suggests either that people with PD have a stronger white
coat effect than the other groups, or that their gait is
more impaired by challenges in daily life, such as distractions to attention, clutter, etc.
Gait in people with MS

Long double-support time, slow gait speed, and short
swing time (all affected by balance impairment and
fatigue) [7, 9, 52] were significantly different daily life gait
measures in MS from MS-Ctl. Indeed, gait speed double-support time and swing time as a percent of the gait
cycle all discriminated gait in people with MS from gait
in healthy control people over a week of daily life with a
similar, excellent area under the curve [35]. In contrast, in
the laboratory, the toe-off angle was the only laboratory
gait measure that discriminated our mild-moderate MS
from MS-Ctl group during comfortable-pace gait after
Bonferroni’s correction for 13 gait characteristics. This
result is consistent with our previous report of a small
toe-off angle in a separate group of people with MS during a 2-min walk in the laboratory [53]. The toe-off angle
is a surrogate for the push-off phase of gait produced by
the power in the gastrocnemius-soleus complex, responsible for stride length and gait speed.

Gait in people with PD

Slow gait speed (representing hypokinetic gait) and
small foot strike angle (representing shuffling of gait)
were significantly different daily life gait measures in
the PD group compared to the PD-Ctl group. Previous
studies of gait in daily life agree that foot strike angle
[35], and gait speed [14] discriminated gait in PD from
healthy control groups. Surprisingly, none of the laboratory gait measures discriminated gait characteristics in mild-moderate PD (ON state), from the PD-Ctl
group, after Bonferroni’s correction, suggesting that
monitoring gait during daily life is more sensitive to
impairments from PD than gait test in the laboratory.
The participants with PD showed much larger changes
in their gait parameters between the laboratory and
daily life than the controls or people with MS. This difference in performance in a laboratory test and daily
life in people with PD may be due to their reliance on
less automatic, more attention demanding gait mechanisms that would make gait in daily life more challenging [54]. The difference could also be due to people with
PD being more prone to placebo effects and white coat
effects than the other groups, so they perform better
when their performance is observed. Alternatively, it
might be that we picked up the ON and OFF fluctuations during daily life that influenced the averaged gait
measures over a week. Nevertheless, assessing mobility
during daily life resulted in more sensitive and specific
differences in gait characteristics than laboratory gait
between the PD and control groups.
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Trunk control during gait

Interestingly, the lumbar coronal range of motion was
one of the top gait measures discriminating both the MS
and PD groups from their age-matched controls in the
laboratory, but not in daily life. The inability of lumbar
motion to discriminate during daily life might be due to
lumbar sensor measures being affected by the exact location of the sensor. In the laboratory, the researchers make
sure the lumbar sensor location is consistent and stays
securely attached throughout the testing, for all subjects,
but it is hard to maintain a consistent sensor location
placed by the subject in daily life conditions, and thus
might not a reliable measure during daily life. Reduced
lumbar range of motion while walking may reflect axial
rigidity and loss of arm swing in the PD group [55], and
may reflect the compensatory strategy to truncal ataxia in
the MS group. In contrast to the reduced lumbar range of
motion in the MS group here, our previous study found
an excessive lumbar motion in people with very early MS
who had normal gait speed [52].
Bout length

Longer bout lengths, such as in 1-min laboratory tests,
are known to result in faster gait speed and other accompanying measures [5, 14]. There are various ways to measure the bout length. Researchers have used bout duration
[5, 14, 31], and the distance traveled during a particular walk test [32] as bout length measures. We chose to
define bout length in terms of a number of strides in the
bout because it helps to eliminate the effect of gait speed,
per se, on the bout length. Most gait bouts during daily
life have < 15 strides in all 4 groups so the 7 m × 2 in the
ISAW test reflected the most common bout lengths people actually take during daily life.
Clinical implication

Our results suggest that clinicians should consider quantitative daily life gait behavior as an integral part of a
functional clinical assessment. Furthermore, this study
provides encouraging results to support the use of instrumented socks for daily life gait evaluation in people with
PD and MS, and also a potential to use in clinical trials,
with a possibility that fewer subjects will be required
for clinical trials using this quantitative measurement of
mobility in daily life.
Limitations

Fig. 4 Wilcoxon paired test comparing laboratory versus daily life
gait characteristics for each group (MS, MS-Ctl, PD, and PD-Ctl)

There are several limitations of the current study. First,
we had a modest sample size of only 15–16 subjects in
each group. This also resulted in a modest statistical
power for detecting differences. If a larger number of
subjects had been included, additional measures would
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have been able to discriminate between the neurological groups from their matched controls. Further analysis
is needed with larger cohorts to test the generalizability
of the findings. Second, we used a conservative correction for multiple hypothesis tests. Many of the tests we
performed were on measures of gait that at correlated
and not statistically independent. The Bonferroni correction assumes these tests are independent, so the correction may have reduced the power of the statistical tests
so that additional measures are actually statistically significant. Thirdly, for daily life data, we assumed that subjects attempt to be in the ON-medication state most of
the time, and hence, we compared with laboratory walking test only with subjects with their ON state. Further,
future studies need to determine the test–retest reliability and sensitivity of the top mobility measures to a treatment and disease progression in daily life to be useful as
digital biomarkers for clinical trials. Finally, with larger
cohorts, we can investigate if the paired ROCs in a laboratory and daily life are statistically significant.

Conclusions
Subjects, especially people with PD, generally showed
better gait characteristics when observed in the laboratory compared to over a week of daily life. Different types
of gait characteristics discriminated PD gait or MS gait
from their age-matched controls in the laboratory versus daily life. PD and MS gait differed from each other,
so clinical trials need to identify the specific gait impairments most sensitive for each neurological disease.
Supplementary information
Supplementary information accompanies this paper at https://doi.
org/10.1186/s12984-020-00781-4.
Additional file 1. Table S1. Gait measures and definitions.
Acknowledgements
We thank our participants for generously donating their time to participate,
and Graham Harker for helping with data collection.
Authors’ contributions
1) Research project: A. Conception: FBH, MM, MEG, JGN, RIS, JM, PCK; B.
Organization: FBH, PCK, CC, VVS; C. Execution: PCK, VVS, MEG; 2) Statistical
Analysis: A. Design: VVS, FBH; B. Execution: VVS; C. Review and Critique: VVS,
JM, MM, CC, FBH; 3) Manuscript: A. Writing of the first draft: VVS; B. Review
and Critique: VVS, JM, MM, JGN, RIS, PCK, CC, MEG, FBH. All authors read and
approved the final manuscript.
Funding
This study was supported by the National Multiple Sclerosis Society Mentor
Fellowship (MB0027; FBH), and National Institutes of Health Grants from the
National Institute on Aging (#1R44AG055388; FBH).
Data availability
The data that support the findings of this study are available from the cor‑
responding author upon reasonable request.

Page 10 of 12

Ethics approval and consent to participate
The study was carried out in accordance with the recommendations of the
Oregon Health & Science University (OHSU) institutional review board (IRB)
with written informed consent from all subjects. All subjects gave written
informed consent in accordance with the Declaration of Helsinki. The proto‑
cols were approved by the OHSU IRB (#15578).
Consent for publication
Not applicable.
Competing interests
Drs. McNames, El-Gohary, and Horak have a significant financial interest in
APDM Wearable Technologies, a company that may have a commercial inter‑
est in the results of this research and technology. Dr. Horak also consults with
Biogen, Neuropore, Sanofi, and Takeda. Dr. Spain consults with TG therapeu‑
tics. These potential conflicts of interest have been reviewed and managed by
OHSU.
Author details
1
Department of Neurology, Oregon Health & Science University, 3181 SW Sam
Jackson Park Road, Portland, OR 97239‑3098, USA. 2 Department of Electri‑
cal and Computer Engineering, Portland State University, Portland, OR, USA.
3
APDM Wearable Technologies, Portland, OR, USA. 4 Veterans Affairs Portland
Health Care System, Portland, OR, USA. 5 Department of Biomechanics, Univer‑
sity of Nebraska At Omaha, Omaha, NE, USA.
Received: 29 June 2020 Accepted: 25 October 2020

References
1. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level
gait disorders, particularly in the elderly. Neurology. 1993;43(2):268–79.
2. Snijders AH, van de Warrenburg BP, Giladi N, Bloem BR. Neurological gait
disorders in elderly people: clinical approach and classifi cation. Neurol‑
ogy. 2007;6(1):63–74.
3. Baker JM. Gait disorders. Am J Med. 2018;131(6):602–7. https://doi.
org/10.1016/j.amjmed.2017.11.051.
4. Galperin I, Hillel I, Del Din S, Bekkers EMJ, Nieuwboer A, Abbruzzese G,
Avanzino L, Nieuwhof F, et al. Associations between daily-living physical
activity and laboratory-based assessments of motor severity in patients
with falls and Parkinson’s disease. Park Relat Disord. 2019;62:85–90.
5. Hillel I, Gazit E, Nieuwboer A, Avanzino L, Rochester L, Cereatti A, et al. Is
every-day walking in older adults more analogous to dual-task walking or
to usual walking? Elucidating the gaps between gait performance in the
lab and during 24/7 monitoring. Eur Rev Aging Phys Act. 2019;16(6):1–12.
6. Warmerdam E, Hausdorff JM, Atrsaei A, Zhou Y, Mirelman A, Aminian K,
et al. Long-term unsupervised mobility assessment in movement disor‑
ders. Lancet Neurol. 2020;19(5):462–70. https://doi.org/10.1016/S1474
-4422(19)30397-7.
7. Morris ME, Cantwell C, Vowels L, Dodd K. Changes in gait and fatigue
from morning to afternoon in people with multiple sclerosis. J Neurol
Neurosurg Psychiatry. 2002;2:361–5.
8. Benedetti MG, Piperno R, Simoncini L, Bonato P, Tonini A, Giannini S. Gait
abnormalities in minimally impaired multiple sclerosis patients. Mult Scler
J. 1999;5:363–8.
9. Cameron MH, Wagner JM. Gait abnormalities in multiple sclerosis: patho‑
genesis, evaluation, and advances in treatment. Curr Neurol Neurosci
Rep. 2011;11:507–15.
10. Peterson DS, Horak FB. Neural control of walking in people with parkin‑
sonism. Physiology. 2016;31(2):95–107.
11. Studenski S, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, et al.
Gait speed and survival in older adults. JAMA. 2011;305(1):50–8.
12. Hale LA, Pal J, Becker I. Measuring free-living physical activity in adults
with and without neurologic dysfunction with a triaxial accelerometer.
Arch Phys Med Rehabil. 2008;89(9):1765–71.
13. Chastin SFM, Baker K, Jones D, Burn D, Granat MH, Rochester L. The pat‑
tern of habitual sedentary behavior is different in advanced Parkinson’s
disease. Mov Disord. 2010;25(13):2114–20.

Shah et al. J NeuroEngineering Rehabil

(2020) 17:159

14. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait char‑
acteristics in ageing and Parkinson’s disease: impact of environment
and ambulatory bout length. J Neuroeng Rehabil. 2016;13(1):1–12.
https://doi.org/10.1186/s12984-016-0154-5.
15. Mancini M, Schlueter H, El-Gohary M, Mattek N, Duncan C, Kaye J, et al.
Continuous monitoring of turning mobility and its association to falls
and cognitive function: a pilot study. J Gerontol Ser A Biol Sci Med Sci.
2016;71(8):1102–8.
16. Bernad-Elazari H, Herman T, Mirelman A, Gazit E, Giladi N, Hausdorff
JM. Objective characterization of daily living transitions in patients
with Parkinson’s disease using a single body-fixed sensor. J Neurol.
2016;263(8):1544–51.
17. De Lima ALS, Hahn T, Evers LJW, De Vries NM, Cohen E, Afek M, et al.
Feasibility of large-scale deployment of multiple wearable sensors in
Parkinson’s disease. PLoS ONE. 2017;12(12):1–15.
18. Adams JL, Dinesh K, Xiong M, Tarolli CG, Sharma S, Sheth N, et al. Multi‑
ple wearable sensors in Parkinson and Huntington disease individuals:
a pilot study in clinic and at home. digit biomarkers. 2017;1(1):52–63.
19. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, SchjodtEriksen J, et al. Evaluation of smartphone-based testing to generate
exploratory outcome measures in a phase 1 Parkinson’s disease clinical
trial. Mov Disord. 2018;33(8):1287–97.
20. Arora S, Baig F, Lo C, Barber TR, Lawton MA, Zhan A, et al. Smartphone
motor testing to distinguish idiopathic REM sleep behavior disorder,
controls, and PD. Neurology. 2018;91(16):e1528–38.
21. Zhan A, Mohan S, Tarolli C, Schneider RB, Adams JL, Sharma S, et al.
Using smartphones and machine learning to quantify Parkinson
disease severity the mobile Parkinson disease score. JAMA Neurol.
2018;75(7):876–80.
22. Mancini M, Weiss A, Herman T, Hausdorff JM. Turn around freezing:
community-living turning behavior in people with Parkinson’s disease.
Front Neurol. 2018;9:1–9.
23. Weiss A, Sharifi S, Plotnik M, Van Vugt JPP, Giladi N, Hausdorff JM.
Toward automated, at-home assessment of mobility among patients
with Parkinson disease, using a body-worn accelerometer. Neuroreha‑
bil Neural Repair. 2011;25(9):810–8.
24. Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE.
Capturing ambulatory activity decline in parkinson’s disease. J Neurol
Phys Ther. 2012;36(2):51–7.
25. Lord S, Godfrey A, Galna B, Mhiripiri D, Burn D, Rochester L. Ambulatory
activity in incident Parkinson’s: More than meets the eye? J Neurol.
2013;260(12):2964–72.
26. Weiss A, Brozgol M, Dorfman M, Herman T, Shema S, Giladi N, et al.
Does the evaluation of gait quality during daily life provide insight
into fall risk? A novel approach using 3-Day accelerometer recordings.
Neurorehabil Neural Repair. 2013;27(8):742–52.
27. Weiss A, Herman T, Giladi N, Hausdorff JM. Objective assessment of fall
risk in Parkinson’s disease using a body-fixed sensor worn for 3 days.
PLoS ONE. 2014;9:5.
28. El-Gohary M, Pearson S, McNames J, Mancini M, Horak F, Mellone S,
et al. Continuous monitoring of turning in patients with movement
disability. Sensors (Switzerland). 2014;14(1):356–69.
29. Benka Wallen M, Franzen E, Nero H, Hagstromer M. Levels and patterns
of physical activity and sedentary behavior in elderly people with mild
to moderate Parkinson disease. Phys Ther. 2015;95(8):1135–41.
30. Mancini M, El-Gohary M, Pearson S, Mcnames J, Schlueter H, Nutt JG,
et al. Continuous monitoring of turning in Parkinson’s disease: Rehabili‑
tation potential. NeuroRehabilitation. 2015;37(1):3–10.
31. Storm FA, Nair KPS, Clarke AJ, Van der Meulen JM, Mazz C. Free-living
and laboratory gait characteristics in patients with multiple sclerosis.
PLoS ONE. 2018;13(5):1–15.
32. Carcreff L, Gerber CN, Paraschiv-Ionescu A, De Coulon G, Newman
CJ, Aminian K, et al. Comparison of gait characteristics between
clinical and daily life settings in children with cerebral palsy. Sci Rep.
2020;10(1):1–11.
33. Shema-Shiratzky S, Hillel I, Mirelman A, Regev K, Hsieh KL, Karni A, et al.
A wearable sensor identifies alterations in community ambulation in
multiple sclerosis: contributors to real - world gait quality and physical
activity. J Neurol. 2020;267:1912–21. https://doi.org/10.1007/s0041
5-020-09759-7.

Page 11 of 12

34. Shah VV, McNames J, Harker G, Mancini M, Carlson-Kuhta P, Nutt JG,
El-Gohary M, Curtze C, et al. Effect of bout length on gait measures in
people with and without parkinson’s disease during daily life. Sensors
(Basal). 2020;20(20):5769. https://doi.org/10.3390/s20205769.
35. Shah VV, McNames J, Mancini M, Carlson-Kuhta P, Spain RI, Nutt JG,
et al. Quantity and quality of gait and turning in people with multiple
sclerosis, Parkinson’s disease and matched controls during daily living.
J Neurol. 2020;267(4):1188–96. https://doi.org/10.1007/s00415-02009696-5.
36. Mancini M, King L, Salarian A, Holmstrom L, James M, Horak FB.
Mobility lab to assess balance and gait with synchronized bodyworn sensors. J Bioeng Biomed Sci. 2011;Suppl 1:007. https://doi.
org/10.4172/2155-9538.S1-007.
37. Kurtzke JF. Rating neurologic impairment in multiple scle‑
rosis: an expanded disability status scale (EDSS). Neurology.
1983;33(11):1444–53.
38. Collins CDE, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin DS, et al.
A comparative analysis of Patient-Reported Expanded Disability Status
Scale tools. Mult Scler J. 2016;22(10):1349–58.
39. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring
the impact of MS on walking ability The 12-Item MS Walking Scale (
MSWS-12). Neurology. 2003;60(1):31–6.
40. Flachenecker P, Ku T, Kallmann B, Gottschalk M, Grauer O, Rieckmann
P. Fatigue in multiple sclerosis: a comparison of different rating scales
and correlation to clinical parameters. Mult Scler J. 2002;8(6):523–6.
41. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin
P, et al. Movement Disorder Society-Sponsored Revision of the Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and
clinimetric testing results. Mov Disord. 2008;23(15):2129–70.
42. Shah VV, McNames J, Mancini M, Carlson-Kuhta P, Nutt JG, El-Gohary M,
et al. Digital biomarkers of mobility in Parkinson’s disease during daily
living. J Parkinsons Dis. 2020;9(10):1099–111. https://doi.org/10.3233/
JPD-201914.
43. Washabaugh EP, Kalyanaraman T, Adamczyk PG, Claflin ES, Krishnan C.
Validity and repeatability of inertial measurement units for measuring
gait parameters. Gait Posture. 2016;2017(55):87–93.
44. Morris R, Stuart S, McBarron G, Fino PC, Mancini M, Curtze C. Validity
of mobility lab (version 2) for gait assessment in young adults, older
adults and Parkinson’s disease. Physiol Meas. 2019;40(9):1–8. https://
doi.org/10.1088/1361-6579/ab4023.
45. Wan EA, Van Der Merwe R. The unscented kalman filter for nonlinear
estimation. Proc IEEE Adapt Syst Signal Process Commun Control
Symp. 2000;23:153–8.
46. van der Merwe R, Wan E. Sigma-point kalman filters for probabilistic
inference in dynamic state-space models. Oregon: Oregon Health and
Science University; 2004.
47. Salarian A, Horak FB, Zampieri C, Carlson-Kuhta P, Nutt JG. iTUG, a sensi‑
tive and reliable measure of mobility. IEEE Trans Neural Syst Rehabil
Eng. 2010;18(3):303–10.
48. Tamburini P, Storm F, Buckley C, Bisi CM, Stagni R, Mazzà C. Moving
from laboratory to real life conditions: influence on the assessment of
variability and stability of gait. Gait Posture. 2018;59:248–52. https://
doi.org/10.1016/j.gaitpost.2017.10.024.
49. Rennie L, Löfgren N, Moe-Nilssen R, Opheim A, Dietrichs E, Franzén
E. The reliability of gait variability measures for individuals with
Parkinson’s disease and healthy older adults–The effect of gait
speed. Gait Posture. 2018;62:505–509. https://doi.org/10.1016/j.gaitp
ost.2018.04.011.
50. Riva F, Bisi MC, Stagni R. Gait variability and stability measures:
minimum number of strides and within-session reliability. Comput
Biol Med. 2014;50:9–13. https://doi.org/10.1016/j.compbiomed
.2014.04.001.
51. Turck N, Vutskits L, Sanchez-Pena P, Robin X, Hainard A, Gex-Fabry M,
et al. pROC: an open-source package for R and S+ to analyze and
compare ROC curves. BMC Bioinformatics. 2011;8:12–77. https://doi.
org/10.1007/s00134-009-1641-y.
52. Spain RI, St George RJ, Salarian A, Mancini M, Wagner JM, Horak FB,
et al. Body-worn motion sensors detect balance and gait deficits
in people with multiple sclerosis who have normal walking speed.
Gait Posture. 2012;35(4):573–78. https://doi.org/10.1016/j.gaitp
ost.2011.11.026.

Shah et al. J NeuroEngineering Rehabil

(2020) 17:159

53. Alberto L, Nogueira C, Teixeira L, Sabino P, Filho HA, Maria R, et al.
Gait characteristics of multiple sclerosis patients in the absence of
clinical disability ait characteristics of multiple sclerosis patients in the
absence. Disabil Rehabil. 2013;35(17):1472–8.
54. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive func‑
tion and attention in Gait. Mov Disord. 2008;23(3):329–42. https://doi.
org/10.1002/mds.21720.
55. Mancini M, Horak FB. Potential of APDM mobility lab for the monitor‑
ing of the progression of Parkinson’s disease. Expert Rev Med Devices.
2016;13(5):455–62. https://doi.org/10.1586/17434440.2016.1153421.

Page 12 of 12

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

